Lilly’s Cymbalta Wins FDA Approval For Major Depression Maintenance Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The battle with Wyeth’s competing SNRI Effexor XR for new indications continues; Cymbalta could see an indication for fibromyalgia in 2008.
You may also be interested in...
Lilly Wins Fibromyalgia Management Indication For Cymbalta
The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.
Lilly Wins Fibromyalgia Management Indication For Cymbalta
The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.
Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.